AmoyDx® Pan Lung Cancer PCR Panel Approved in Japan as The Primary Companion Diagnostic for IBTROZI® (Taletrectinib adipate)

TOKYO and XIAMEN, September 19, 2025 — Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. (“AmoyDx”), and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”) as a Companion Diagnostic (CDx) for Taletrectinib adipate　(IBTROZI®).

Read the full release here:

JointRelease_ROS1_Taletrectinib_approval_RG-Amoy-PREMIA.pdf

Download PDF • 225KB